Four changes included in new case definition, including no required duration of subjective or measured fever<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, Dec. 19, 2022 (HealthDay News) — A new surveillance case definition for multisystem inflammatory syndrome in children (MIS-C) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been developed, according to research published in the Dec. 16 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report<\/em>.<\/p>\n Michael Melgar, M.D., from the CDC COVID-19 Response Team, and colleagues developed a Council of State and Territorial Epidemiologists (CSTE) and CDC position statement that includes an MIS-C surveillance case definition for voluntary reporting to the CDC, which comes into effect Jan. 1, 2023.<\/p>\n The methods used to develop the definition included convening MIS-C clinical experts regarding identification of MIS-C and its distinction from other pediatric conditions, a review of the literature comparing the MIS-C phenotype to that of other syndromes, and retrospective application of different criteria to data from previously reported MIS-C cases. The authors note that four important changes are included in the CSTE\/CDC surveillance case definition versus the 2020 CDC MIS-C case definition: (1) no required duration of subjective or measured fever; (2) requirement for C-reactive protein \u00e2\u0089\u00a53.0 mg\/dL; (3) adjustments to criteria of organ system involvement to include shock as a distinct category and eliminate respiratory, neurologic, and renal criteria; and (4) new requirements of timing of positive SARS-CoV-2 laboratory testing relative to MIS-C.<\/p>\n “Continued surveillance will be crucial as new SARS-CoV-2 variants of concern emerge and circulate in the United States and vaccination recommendations expand to include younger children, potentially altering the epidemiology of MIS-C,” the authors write.<\/p>\n